Multiple Sclerosis Treatment Industry Overview

• Publication date: March 2009
• Report size: 29 pages

Only about 36% of Multiple Sclerosis (MS) patients are currently treated with MS drugs, this percentage is expected to increase to 56% by 2014 as new oral MS therapies are launched, which shows bright opportunity for oral drugs in multiple sclerosis industry . The injectables industry is big but leaves certain side effects which bring the possibility for the oral drugs to succeed. It is expected that oral drugs will bring some ease for the patien...

Only about 36% of Multiple Sclerosis (MS) patients are currently treated with MS drugs, this percentage is expected to increase to 56% by 2014 as new oral MS therapies are launched, which shows bright opportunity for oral drugs in multiple sclerosis industry . The injectables industry is big but leaves certain side effects which bring the possibility for the oral drugs to succeed. It is expected that oral drugs will bring some ease for the patients. In Canada the prevalence rate of MS is the highest with closely followed by United States which is the second most affected region with increasing death rates of MS patients. Also the prevalence rate in Germany, Norway and Hungary is high. In 2008 the MS treatment industry has shown good results despite the slowdown in US and with this success the probability for further growth has increased.

Gender has become a dominant factor in MS during the last decades. The studies have proved that MS prevalence rate is higher in women than man, but the cause of the disease has not been found. MS is the fourth leading cause of disability among American women. Early Age Smoking is also one of the major environmental factors which have increased the chances of MS disease. MS is slowly spreading its reach in the Asian regions. Asia can be a potential industry in future.

This report analyses the global multiple sclerosis industry demand and potential opportunities prevailing in the industry . It gives an overview of the disease and prevalence worldwide, also covers the total industry for MS treatment. It presents global MS injectable industry growth and discussion of various medicines industry share. The report also focuses on the growth of the market in United States. It gives an overview of the trends and opportunities present in the market . It also analyses competition in the industry with an overview of market players and their business strategies.

Pharmaceutical Industry in the United States

I. Introduction: Multiple Sclerosis

Relapsing-remitting MS
Secondary Progressive MS
Primary Progressive MS
Progressive-relapsing MS

I. 1 FDA-Approved Drugs for the Treatment of Multiple Sclerosis

II. Global Multiple Sclerosis Industry

II. 1 Industry Value

Market Value
Prevalence Rate
Mortality Statistics

II. 2 Multiple Sclerosis Injectable: Industry Share
Injectables Industry Value
Market Share

III. US Multiple Sclerosis Industry

Market Overview
Prevalence Rate

III. 1 U.S. Injectables Industry

MS Injectables Industry

IV. Market Trends

IV. 1 Prevalence of CRPS in Multiple Sclerosis Patients
IV. 2 Environment Causes Increase in Multiple Sclerosis Cases
IV. 3 Increasing Female to Male ratio for Multiple Sclerosis
IV. 4 Demand of MS Diagnosis

V. Opportunities

V. 1 Oral MS Drugs to Replace Injectables
V. 2 Opportunities in Asian Region

VI. Competitive Environment

Market Share

VII. Industry Player s

VII. 1 Teva Pharmaceutical Market

Overview
Business Strategies
Expanding its Reach
Broad Product Portfolio
Operating Leverage

VII. 2 Biogen

Overview
Business Strategies
Strategic Agreements
Vast Geographical Presence

VII. 3 Elan Corporation

Overview
Business Strategies
Collaborations and Agreements

VII. 4 Merck Serono S.A.

Overview
Business Strategies
Expansion Project for Erbitux
Diversified Geographic Presence
Broad Product portfolio

VIII. Industry Outlook

List of Tables

FDA-Approved Drugs for the Treatment of Multiple Sclerosis
Population Suffering from MS and Prevalence Rate by Region
US Multiple Sclerosis Injectables Industry by Penetration Rate (2005-10E)
US Multiple Sclerosis Injectables Industry Value by Drugs (2005-08E)
Expected Prevalence of CRPS in MS Patients by Age Group (2007)
Oral Drugs in Late-stage Development for MS
Competing Drugs in Development for MS

List of Charts

Mortality Statistics by Multiple sclerosis by Region (2007)
Market Value of Multiple Sclerosis Treatment (2001-08)
Multiple Sclerosis Injectable Industry Share (2007)
MS Injectables Industry Value by Drugs (2007)
Tysabri MS Industry Value & Projection (2007-09E)
Avonex Industry Value & Projection (2005-12E)
Multiple Sclerosis Prevalence in United States (2005-14E)
US MS Affected Population by Categories (2006)
Tysabri Industry in United States (2006-08)
Avonex Industry Value & Projection for US (2005-12E)
Smoking Among High School Students vs. Men (2001-05)
Number of Deaths Attributable to Smoking in China (2005)
Male/female Ratio of MS in WHO Regions and World (2007)
Commonest MS Diagnostic Criteria Used (2007)
Commonest MS diagnostic Criteria Used in WHO Regions (2007)
US MS Therapies Prescription Trends (2006-07)
US Industry for MS Treatment (2009-12E)
United States MS Drugs Revenue by Class (2009-12E)
Teva Pharmaceutical Revenue by Business Segments (2007-08)
Biogen Revenue by Geography (2006-08)
Elan Corporation Revenue by Business Segments (2006-08)